Health News Releases

  • Today April 13
January 07, 2014 12:55
GE To Expand in Life Sciences with Acquisition of Strategic Assets from Thermo Fisher Scientific
GE (NYSE:GE) and Thermo Fisher Scientific (NYSE:TMO) announced today that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gen
January 07, 2014 10:50
Quintiles Executive to Present at J.P. Morgan Healthcare Conference
Quintiles CEO Tom Pike will present at the 2014 J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 in San Francisco at the Westin St. Francis Hotel. The Quintiles presentation will b
December 26, 2013 09:10
Menicon, Azabu University, and Yokohama City University Identify the Glaucoma Susceptibility Gene SRBD1 in Dogs
Menicon announces that an article entitled, “Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk”, which presents the results of a study conducted by Menicon, Azabu University,
December 23, 2013 11:54
iHerb Wins 2013 Best International Business Mobile Website
iHerb.com, a leading online retailer of nutritional supplements and wellness products announced today that it won the 2013 Best International Business Mobile Website from The Web Marketing Association
December 23, 2013 10:18
First-in-Man Implantation of CARMAT’s Bioprosthetic Artificial Heart
CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, providing an alternative for people suffering from end-stage heart f
December 19, 2013 10:33
Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsi
December 18, 2013 14:31
Richard Relyea Elected to the Quintiles Transnational Holdings Inc. Board of Directors
Quintiles announced today that Mr. Richard Relyea has been elected to its board of directors. Mr. Relyea was designated by equity investor 3i to fill a vacancy on the Quintiles Transnational Holdin
December 18, 2013 10:31
61% of Life Sciences Execs Identify “Changing Commercial Business Model” as Major Pain Point in Survey by Cegedim Relationship Management
Cegedim Relationship Management today announced the release of their latest thought leadership report, 2013 Global Life Sciences Insights, which offers an analysis of the results of a global survey of
December 18, 2013 09:13
New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism
For media outside of the US, the UK & Canada only New pooled safety data from the RE-COVERTM and RE-COVERTM II phase III trials in acute deep vein thrombosis (DVT) and pulmonary embolism (PE) cons
December 16, 2013 18:14
Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant
For media outside of the US, the UK & Canada only Data show that Boehringer Ingelheim’s second-generation protease inhibitor faldaprevir*, when used in combination with pegylated interferon and ri
Quintiles has appointed Scott Evangelista to lead Integrated Commercial Services and Solutions.
December 13, 2013 15:40
Quintiles Appoints Scott Evangelista to Lead Integrated Commercial Services and Solutions
Quintiles today announced the appointment of W. Scott Evangelista to serve as president, Integrated Commercial Services and Solutions. In this role, Evangelista is responsible for leading Quintiles’ g
December 13, 2013 09:40
Iroko Pharmaceuticals Enters into Strategic Agreements to Expand Commercialization of ZORVOLEXTM (diclofenac) Outside the U.S.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., has signed licens
December 12, 2013 09:00
Heartbeat Experts Reports Company wide Sales Growth of 44% and Over 600% Sales Growth in its Market Access Division
Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, today announced 44 percent sales growth during first three quarters of 2013. Heartbeat Expert’s
December 12, 2013 08:40
New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders
CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soli
December 11, 2013 10:30
electroCore's non invasive VNS treatment for headache highlighted at the recent American Headache Society (AHS) Annual Scottsdale Headache Symposium and the 17th Annual North American Neuromodulation Society (NANS) meeting
electroCore’s non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st
December 11, 2013 09:30
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
For media outside of the US, the UK & Canada only New data analyses show that the positive treatment effect (efficacy and safety profile) of Pradaxa® (dabigatran etexilate) 150mg twice daily was c
Patient LINC's easy to Use, intuitive interface
December 10, 2013 14:25
Lincor Upgrades Patient Engagement Technology, Launches New Product Portfolio
Lincor Solutions today announced the launch of a new portfolio of products for delivering its industry-leading patient engagement technology to hospitals and health systems. Powered by next-generat
December 10, 2013 10:00
Apira Science, Inc. Accelerates Global Growth Through Exclusive Distribution Partnership with China Central Pharmaceuticals
Apira Science, Inc. has named China Central Pharmaceuticals Ltd. its exclusive distributor of the iGrow® Hair Growth System in the Chinese market. The partnership highlights Apira’s growing success in
Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
December 10, 2013 09:17
Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated overall survival data from two ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinica
December 10, 2013 08:40
Updated Data with Oral Proteasome Inhibitor MLN9708 Reported in Newly Diagnosed Multiple Myeloma Patients
Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalido
December 09, 2013 11:55
Celsis and CoValence Recognised for Transformative Supply Chain Project
The collaboration of Celsis International and CoValence Laboratories has been named the 2013 Supply & Demand Chain Executive (SDCE) Top 100 -“100 Great Supply Chain Projects” for delivering measurable
December 03, 2013 17:10
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes
For Non-US and Non-UK Media Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with
December 02, 2013 17:29
Largest global survey investigating early Type 2 Diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation
Boehringer Ingelheim and Eli Lilly and Company today announced the launch of the largest multinational survey to investigate early conversations between physicians and people living with Type 2 Diabet
Gantry Treatment System
December 02, 2013 11:55
Sumitomo Proton Therapy System Clears FDA 510(k)
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo.
KOHI successfully concluded Population and Reproductive Health for Pakistan Program with KOICA.
November 29, 2013 09:28
KOHI successfully concluded ‘Population and Reproductive Health for Pakistan’ Program With KOICA
Korea Human Resource Development Institute for Health and Welfare, KOHI (President; Ryu Hoyoung) successfully concluded ‘Population and Reproductive Health for Pakistan’ Program with KOICA. Delegates
25 per page50 per page75 per page100 per page